Reports: Google Flu Trends may have overestimated epidemic
NEW YORK — Google seems to have found a nifty niche for itself with Google Flu Trends, which seeks to track the influenza outbreak by monitoring Web searches for flu-related topics, but its accuracy may be in doubt, according to published reports.
Nature reported that a comparison between data from Google Flu Trends and official surveillance data found that the Google tool had overestimated peak flu levels. Nevertheless, according to Nature, the problem is minor, and the Internet services giant will probably be able to fix it.
Traditionally, flu tracking has been the work of agencies like the Centers for Disease Control and Prevention in the United States and France’s Sentinelles network. Nature quoted a French epidemiologist as saying that newer systems for tracking flu depend too much on existing ones.
ScriptPro wins top spot in KLAS rankings
MISSION, Kan. — Pharmacy automation system manufacturer ScriptPro has received a top spot from a research firm that specializes in monitoring and reporting on the performance of healthcare vendors.
ScriptPro said the healthcare IT research firm KLAS ranked its SP Central Pharamcy Management System No. 1 in the category of Software Solutions – Pharmacy – Outpatient (Retail) in the "2012 Best in KLAS Award: Software & Services."
"We really value the KLAS ratings. They give us objective information on how we’re doing from the perspective of our customers," ScriptPro president and CEO Mike Coughlin said. "They also help focus the attention of our team on the all-important mission of continuously improving and providing products and services that we can all be proud of."
Actavis can launch generic painkiller in May 2014 under settlement
PARSIPPANY, N.J. — Actavis and Mallinckrodt have reached a settlement concerning the former’s generic version of an opioid painkiller made by the latter, Actavis said Thursday.
The companies settled patent lawsuit regarding Actavis’ generic version of Mallinckrodt’s Exalgo (hydromorphone hydrochloride) extended-release tablets in the 32-mg strength. The companies settled litigation regarding the 8-mg, 12-mg and 16-mg strengths last month.
Under the settlement, Mallinckrodt granted Actavis a loyalty-free license to its U.S. patents on Exalgo, allowing Actavis to start selling the 32-mg strength in generic form starting in May 2014. Actavis said it was likely the first company to file for Food and Drug Administration approval of a generic version of the drug, which would entitle it to 180 days in which to compete exclusively against the branded version after approval.